Chemomab Therapeutics Ltd.
CMMB Nasdaq· Pharmaceutical Preparations
Last close · Oct 30, 2026
$1.16
KIRA · Stoqly’s AI analyst, in plain words
- Chemomab Therapeutics Ltd. lost $9.0M in fiscal 2025. From fiscal 2018 to 2025, diluted EPS grew −44.4% a year.
- Free cash flow was −$11.1M in fiscal 2025. At that burn of $11.1M a year, its $7.6M of cash and short-term investments would last about 0.7 years.
Market cap
—
P/E
—
Revenue
—
Net income
−$9.0M
Free cash flow
−$11.1M
Operating margin
—
Chemomab Therapeutics Ltd. in 30 seconds · fiscal 2025
Does it make a profit?
−$9.0M
No. It lost money last year.
How long would its cash last?
0.7 yrs
Not long. It burns $11.1M a year and holds $7.6M, under a year at that pace, so it may need new money soon.
What Chemomab Therapeutics Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 23, 2026
- Legal name
- Chemomab Therapeutics Ltd.
- CIK
- 0001534248
Chemomab Therapeutics Ltd. · CMMB · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$12.5M | −$27.6M | −$24.2M | −$13.9M | −$9.0M |
| Diluted EPS | $0.06 | $0.12 | $0.10 | $0.04 | $0.02 |
| Cash | |||||
| Cash from operations | −$12.4M | −$20.4M | −$23.6M | −$15.4M | −$11.1M |
| Capital expenditure | $0.2M | $0.1M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$12.6M | −$20.4M | −$23.6M | −$15.4M | −$11.1M |
| Share count change | 51.7% | 9.7% | 3.3% | 52.8% | 42.1% |
| Debt and strength | |||||
| Cash and short-term investments | $15.2M | $13.5M | $9.3M | $6.1M | $7.6M |
| Shareholders' equity | $61.5M | $36.2M | $17.0M | $13.5M | $12.3M |
| Current ratio | 23.7x | 6.2x | 4.3x | 5.0x | 9.1x |
| Returns and quality | |||||
| Return on equity | −34.5% | −56.6% | −91.0% | −91.3% | −69.5% |
| Return on tangible equity | −20.3% | −76.3% | −142.5% | −103.0% | −72.9% |
| Altman Z'' | — | — | — | −51.4 | −66.4 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Chemomab Therapeutics Ltd. · CMMB · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.16 a share, the company is worth —.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001534248). Latest version: stoqly.net/companies/cmmb. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.